Alkermes Plc ALKS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
24.74UNCH (UNCH)
Volume
38,589
Close
24.74quote price arrow up+0.32 (+1.31%)
Volume
856,910
52 week range
15.35 - 25.47

...

Loading . . .
  • Open24.62
  • Day High24.92
  • Day Low24.55
  • Prev Close24.42
  • 52 Week High25.47
  • 52 Week High Date06/14/21
  • 52 Week Low15.35
  • 52 Week Low Date10/28/20

Key Stats

  • Market Cap3.97B
  • Shares Out160.45M
  • 10 Day Average Volume1.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change24.01

KEY STATS

  • Open24.62
  • Day High24.92
  • Day Low24.55
  • Prev Close24.42
  • 52 Week High25.47
  • 52 Week High Date06/14/21
  • 52 Week Low15.35
  • 52 Week Low Date10/28/20
  • Market Cap3.97B
  • Shares Out160.45M
  • 10 Day Average Volume1.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change24.01

RATIOS/PROFITABILITY

  • EPS (TTM)-0.59
  • P/E (TTM)-41.62
  • Fwd P/E (NTM)80.32
  • EBITDA (MRQ)-10.60M
  • ROE (MRQ)-8.95%
  • Revenue (MRQ)1.044B
  • Gross Margin (MRQ)83.51%
  • Net Margin (MRQ)-9.06%
  • Debt To Equity (MRQ)28.32%

EVENTS

  • Earnings Date07/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alkermes Plc

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA...
Richard Pops
Chairman
Blair Jackson
Chief Operating Officer
Iain Brown
Chief Financial Officer
Craig Hopkinson M.D.
Executive Vice President
Address
Connaught HSE, 1 Burlington Road
Dublin
00000
Ireland